Skip to main content

Search

3 result(s) for 'author#Lang’o Odondi' within BMC

Page 1 of 1

Sort by: Relevance | Date

  1. Standard therapy for borderline-resectable pancreatic cancer in the UK is surgery with adjuvant chemotherapy, but rates of resection with clear margins are unsatisfactory and overall survival remains poor. Met...

    Authors: Daniel L. P. Holyoake, Elizabeth Ward, Derek Grose, David McIntosh, David Sebag-Montefiore, Ganesh Radhakrishna, Neel Patel, Michael Silva, Somnath Mukherjee, Victoria Y. Strauss, Lang’o Odondi, Emmanouil Fokas, Alan Melcher and Maria A. Hawkins
    Citation: BMC Cancer 2016 16:728
    Content type: Study protocol Published on:

  2. The continual reassessment method (CRM) is a model-based design for phase I trials, which aims to find the maximum tolerated dose (MTD) of a new therapy. The CRM has been shown to be more accurate in targeting...

    Authors: Graham M. Wheeler, Adrian P. Mander, Alun Bedding, Kristian Brock, Victoria Cornelius, Andrew P. Grieve, Thomas Jaki, Sharon B. Love, Lang’o Odondi, Christopher J. Weir, Christina Yap and Simon J. Bond
    Citation: BMC Medical Research Methodology 2019 19:18
    Content type: Technical advance Published on:

  3. Adaptive designs can make clinical trials more flexible by utilising results accumulating in the trial to modify the trial’s course in accordance with pre-specified rules. Trials with an adaptive design are of...

    Authors: Philip Pallmann, Alun W. Bedding, Babak Choodari-Oskooei, Munyaradzi Dimairo, Laura Flight, Lisa V. Hampson, Jane Holmes, Adrian P. Mander, Lang’o Odondi, Matthew R. Sydes, Sofía S. Villar, James M. S. Wason, Christopher J. Weir, Graham M. Wheeler, Christina Yap and Thomas Jaki
    Citation: BMC Medicine 2018 16:29
    Content type: Correspondence Published on: